Anlon Healthcare IPO Day 1: Check GMP, Subscription Status & Key Highlights
The IPO bidding window for the Anlon Healthcare IPO is open today, August 26, 2025, and will close on August 29, 2025. One day prior to the IPO opening, the company had raised ₹48.37 crore from its anchor investors on August 25, 2025.
Anlon Healthcare IPO: Issue Details
Anlon Healthcare IPO is a book-building issue of ₹121.03 crores, consisting entirely of a fresh issue of 1.33 crore shares. The price band is set between ₹86 and ₹91 per share. The basis of allotment will be finalised by September 1, 2025, and the tentative listing date on BSE and NSE is September 3, 2025.
Anlon Healthcare IPO Day 1 Subscription Status
[26-August-2025, 17:00:00]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.91 |
|
Non-Institutional Investors |
0.71 |
|
Retail Individual Investors (RIIs) |
8.98 |
|
Total |
1.69 |
Utilisation of IPO Proceeds
The net proceeds from the fresh will be used towards:
- Funding capital expenditure towards the expansion of the manufacturing facility
- Funding working capital requirements
- Repayment/prepayment of the company’s outstanding borrowings
- General corporate purposes
Check out newly Listed IPOs on BSE and NSE.
Anlon Healthcare IPO GMP Details
As of 26 August 2025, Anlon Healthcare IPO’s GMP stood at ₹5. The estimated listing price is ₹96, i.e., a 5.49% gain per share over the upper price band.
|
Source: Business Standard Report dated 26 August, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor do we recommend or endorse trading in the grey market. |
Explore other Upcoming IPOs on BSE and NSE.
Anlon Healthcare Business Overview
Anlon Healthcare is a chemical manufacturing company engaged in the production of high-purity advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs). Their products are used as raw materials in the synthesis of APIs and in the formulation of a wide range of finished dosage forms (FDFs) such as tablets, capsules, syrups, ointments, and more.
The company’s offerings also extend to nutraceutical ingredients, personal care components, and veterinary APIs.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.